Navigation Links
Drugs may Help Turn on Gene Switched Off in Cancer

Researchers from the University of Michigan Comprehensive Cancer Center suggest that drugs may be helpful in switching on a gene implicated in the development of cancer cells , raising hope for the development of a new class of targeted therapies with potential to benefit many different cancer types.

During the study, the researchers found that a gene called Brahma (BRM) was silent, but not missing, in some cancer cells. They found that the gene was turned off in about 15 percent of tumours studied, including cells from lung, oesophageal, ovarian, bladder, colon and breast cancers.

When the BRM gene was exposed to some of the existing inhibitor drugs, it was turned on. The finding attains significance because many times cancers occur when genes that control growth are turned off.

The researcher though concede that new drugs need to be developed to be more effective in reactivating this gene in cancer cells, they insist that their finding may lead to new targets for cancer treatment.

This is a targetable target. We can detect it, but we need to find a better way to turn it back on. No drugs are designed to deal with a gene thats turned off. But its a straightforward extension of current therapies that target genes that are turned on, says lead study author Dr. David Reisman, Assistant Professor of Internal Medicine at the U-M Medical School.

The study, published in the journal Oncogene, involved the use of a class of drugs called histone deacetylase inhibitors, or HDAC inhibitors.

While the existing HDAC inhibitors were found to switch on the BRM gene, the effect was short-lived and reduced as the drugs were taken away. The HDAC inhibitors are not the perfect answer, but in principle this tells us we can turn our gene back on. If we can turn the gene back on, it may not be a cure for cancer, but it could slow it down or make it responsive to existing drugs, Reisman says.

The researchers targeted lung cancer cell lines in particular, although they found similar results in a variety of other cancer cell lines tested. Tumours are not the same from one person to the next, and even the cells within a single tumour are not the same. Giving a single drug or drug combination to 500 people is setting ourselves up for failure, much like a one-size-fits-all clothing store would never succeed, Reisman says.

Targeted therapies are now opening the door, because they are essentially given only to those patients who have a high likelihood of response. Their low toxicity means the patient can be treated for long periods of time, which is unlike older and more traditional chemotherapy agents. Even if these new targeted therapies dont cure the cancer, we can at least have long-term survival, he adds.


'"/>




Related medicine news :

1. Lean Protein Could Be Key to Obesity Drugs
2. Life Saving Cancer Drugs – From Chicken! Possible Says Dolly’ Creatos
3. Nasal Spray Could Take Drugs Direct to Brain.
4. Emphasis to ban Drugs ads by Doctors
5. Osteoporosis Drugs: right time to take-off
6. Drugs disrupt formation of blood vessels
7. Drugs to stop burgeon of HIV
8. Misleading Advertisements for Prescription Drugs
9. Drugs For Anthrax May Interfere With Oral Contraceptives
10. Over-The-Counter Drugs May Prevent Alzheimers
11. Steps To Improve Quality Of Plant-Based Drugs
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/23/2017)... ... February 23, 2017 , ... ... a clinician-based audience, will be participating in Rare Disease Day events, hosted by ... In addition, Rare Disease Report, a website, weekly e-newsletter and quarterly publication, will ...
(Date:2/23/2017)... Hollywood, CA (PRWEB) , ... February 23, 2017 , ... ... pleased to announce that they are sponsoring a raffle. Throughout the month of February, ... Winners will receive a gift card for a dinner for two at the Cheesecake ...
(Date:2/23/2017)... Los Angeles, California (PRWEB) , ... February 23, ... ... for Global Sports Development will host a diverse symposium on “Doping ... School of Law and Sheppard Mullin Richter & Hampton LLP. The symposium will ...
(Date:2/23/2017)... ... February 23, 2017 , ... ERT, a global data and ... Premier Research, a leading clinical development service provider, has selected ERT’s Trial Oversight ... due in part to an array of circumstances including the use of multiple ...
(Date:2/23/2017)... RI (PRWEB) , ... February 23, 2017 , ... ... today a new partnership with the Rhode Island Consortium for Autism Research and ... an opportunity for children with autism spectrum disorder (ASD) to see films in ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... Feb 24, 2017 Medivir AB ... for a new Board of Directors that will be ... Nomination Committee comprises representatives of the company,s three largest ... 2016 who have accepted a seat on the Nomination ... of the 2016-2017 Nomination Committee was as follows:  ...
(Date:2/24/2017)... , Feb 24, 2017 Research and Markets ... Analysis and Strategies - 2016" report to their offering. ... The latest research ... pricing data and benchmarks in the global Urinary Incontinence market. ... What are the key drugs marketed for Urinary Incontinence and their ...
(Date:2/23/2017)... Research and Markets has announced the addition of the "Autism ... to their offering. ... The latest research Autism Spectrum Disorder Drugs Price Analysis and ... global Autism Spectrum Disorder market. The research answers the following ... marketed for Autism Spectrum Disorder and their clinical attributes? How are ...
Breaking Medicine Technology: